PE20140734A1 - Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismas - Google Patents
Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismasInfo
- Publication number
- PE20140734A1 PE20140734A1 PE2013002881A PE2013002881A PE20140734A1 PE 20140734 A1 PE20140734 A1 PE 20140734A1 PE 2013002881 A PE2013002881 A PE 2013002881A PE 2013002881 A PE2013002881 A PE 2013002881A PE 20140734 A1 PE20140734 A1 PE 20140734A1
- Authority
- PE
- Peru
- Prior art keywords
- ids
- composition
- sulfatase
- recombinant human
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) IDURONATO-2-SULFATASA HUMANO RECOMBINANTE (IDS) QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEC ID N�: 1, DONDE EL RESIDUO DE CISTEINA EN POSICION 59 SE CONVIERTE EN FORMILGLICINA (FGly) A UNA PROPORCION MOLAR DE 75%, Y CONTIENE MANOSA-6-FOSFATO EN UNA CANTIDAD DE 2 A 4 MOLES POR MOL DE IDS; B) UNA SUSTANCIA TAL COMO UN TAMPON, UN CARBOHIDRATO, UN ANTIOXIDANTE, UN AGENTE QUELANTE, ENTRE OTROS; Y C) UN PORTADOR FARMACEUTICAMENTE ACEPTABLE. TAMBIEN SE REFIERE A UN METODO PARA PREPARAR LA COMPOSICION QUE COMPRENDE: i) TRANSFORMAR UNA CELULA DE OVARIO DE HAMSTER CHINO CON UN VECTOR DE EXPRESION QUE PORTA UN GEN IDS PARA OBTENER UNA CEPA DE CELULA RECOMBINANTE; ii) CULTIVAR LA CEPA DE CELULA RECOMBINANTE EN PRESENCIA DE UN HIDROLIZADO EN UN MEDIO SIN SUERO Y OBTENER EL CULTIVO; iii) PURIFICAR EL IDS DEL CULTIVO MEDIANTE CROMATOGRAFIA DE INTERCAMBIO DE ANIONES, CROMATOGRAFIA HIDROFOBA, ENTRE OTROS; Y iv) COMBINAR EL IDS PURIFICADO CON UN PORTADOR FARMACEUTICAMENTE ACEPTABLE. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL SINDROME DE HUNTER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500994P | 2011-06-24 | 2011-06-24 | |
| KR1020120012718A KR101158673B1 (ko) | 2011-06-24 | 2012-02-08 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140734A1 true PE20140734A1 (es) | 2014-07-04 |
Family
ID=46716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002881A PE20140734A1 (es) | 2011-06-24 | 2012-06-15 | Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismas |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9206402B2 (es) |
| EP (1) | EP2723369B2 (es) |
| JP (2) | JP5844459B2 (es) |
| KR (2) | KR101158673B1 (es) |
| CN (1) | CN103635203B (es) |
| AU (2) | AU2012274215B2 (es) |
| BR (1) | BR112013032193A2 (es) |
| CA (1) | CA2839674C (es) |
| CO (1) | CO6862105A2 (es) |
| CY (1) | CY1117861T1 (es) |
| DK (1) | DK2723369T4 (es) |
| EA (1) | EA026499B1 (es) |
| ES (1) | ES2575377T5 (es) |
| FI (1) | FI2723369T4 (es) |
| HK (1) | HK1195731A1 (es) |
| HR (1) | HRP20160490T4 (es) |
| HU (1) | HUE027431T2 (es) |
| IL (1) | IL230120B (es) |
| MX (1) | MX341946B (es) |
| MY (1) | MY166647A (es) |
| PE (1) | PE20140734A1 (es) |
| PL (1) | PL2723369T5 (es) |
| PT (1) | PT2723369E (es) |
| RS (1) | RS54822B2 (es) |
| SI (1) | SI2723369T2 (es) |
| SM (1) | SMT201600194B (es) |
| UA (1) | UA109949C2 (es) |
| WO (1) | WO2012177020A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| US20140004097A1 (en) * | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| CN106153744B (zh) * | 2015-03-31 | 2020-11-10 | 三生国健药业（上海）股份有限公司 | 融合蛋白二硫键配对分析方法 |
| CN106153745B (zh) * | 2015-03-31 | 2020-11-10 | 三生国健药业（上海）股份有限公司 | 抗体蛋白二硫键配对分析方法 |
| CN106153746B (zh) * | 2015-03-31 | 2020-11-06 | 三生国健药业（上海）股份有限公司 | IgG2型单抗二硫键配对分析方法 |
| WO2017003270A1 (ko) * | 2015-07-02 | 2017-01-05 | 주식회사 녹십자 | 헌터증후군 치료제 및 치료방법 |
| KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
| DK3397270T3 (da) * | 2015-12-30 | 2024-05-06 | Green Cross Corp | Sammensætninger til anvendelse i behandlingen af hunters syndrom |
| EP3420072A4 (en) * | 2016-02-22 | 2019-08-28 | Agency for Science, Technology and Research | CELL CULTURE MEDIUM |
| IL307936A (en) * | 2017-04-14 | 2023-12-01 | Regenxbio Inc | Treatment for mucopolysaccharidosis 2 with the help of recombinant human iduronate-2 suplatase (ids) produced by human neuron or glial cells |
| JP2020528756A (ja) * | 2017-07-28 | 2020-10-01 | ハンミ ファーマシューティカル カンパニー リミテッド | イズロン酸−２−スルファターゼ結合体 |
| JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 酵素補充療法用酵素を含む融合タンパク質 |
| KR102671857B1 (ko) | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| WO2020050947A2 (en) * | 2018-09-05 | 2020-03-12 | Sangamo Therapeutics, Inc. | Enzymatic assays for quantifying therapy in subjects with mucopolysaccharidosis type i or ii |
| EP3826664A4 (en) | 2019-02-06 | 2022-10-26 | Sangamo Therapeutics, Inc. | METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES |
| CA3209611A1 (en) | 2021-02-10 | 2022-08-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| WO2024144003A1 (ko) * | 2022-12-29 | 2024-07-04 | 주식회사 녹십자 | 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932211A (en) | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
| IL155588A0 (en) * | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| US8227212B2 (en) * | 2003-02-11 | 2012-07-24 | Shire Human Genetic Therapies, Inc. | Cell that expresses a sulfatase and a formylglycine generating enzyme |
| WO2005113765A2 (en) | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
-
2012
- 2012-02-08 KR KR1020120012718A patent/KR101158673B1/ko active IP Right Grant
- 2012-05-24 KR KR1020120055450A patent/KR101910124B1/ko active IP Right Grant
- 2012-06-15 PL PL12803297.6T patent/PL2723369T5/pl unknown
- 2012-06-15 DK DK12803297.6T patent/DK2723369T4/da active
- 2012-06-15 ES ES12803297T patent/ES2575377T5/es active Active
- 2012-06-15 HR HRP20160490TT patent/HRP20160490T4/hr unknown
- 2012-06-15 RS RS20160383A patent/RS54822B2/sr unknown
- 2012-06-15 WO PCT/KR2012/004734 patent/WO2012177020A2/en active Application Filing
- 2012-06-15 CN CN201280030629.XA patent/CN103635203B/zh active Active
- 2012-06-15 BR BR112013032193A patent/BR112013032193A2/pt not_active Application Discontinuation
- 2012-06-15 HU HUE12803297A patent/HUE027431T2/en unknown
- 2012-06-15 MY MYPI2013004575A patent/MY166647A/en unknown
- 2012-06-15 CA CA2839674A patent/CA2839674C/en active Active
- 2012-06-15 AU AU2012274215A patent/AU2012274215B2/en active Active
- 2012-06-15 EA EA201490149A patent/EA026499B1/ru not_active IP Right Cessation
- 2012-06-15 PE PE2013002881A patent/PE20140734A1/es active IP Right Grant
- 2012-06-15 US US14/128,918 patent/US9206402B2/en active Active
- 2012-06-15 FI FIEP12803297.6T patent/FI2723369T4/fi active
- 2012-06-15 MX MX2013015127A patent/MX341946B/es active IP Right Grant
- 2012-06-15 SI SI201230565T patent/SI2723369T2/sl unknown
- 2012-06-15 EP EP12803297.6A patent/EP2723369B2/en active Active
- 2012-06-15 UA UAA201400664A patent/UA109949C2/ru unknown
- 2012-06-15 JP JP2014516901A patent/JP5844459B2/ja active Active
- 2012-06-15 PT PT128032976T patent/PT2723369E/pt unknown
-
2013
- 2013-12-23 IL IL230120A patent/IL230120B/en active IP Right Grant
-
2014
- 2014-01-21 CO CO14010749A patent/CO6862105A2/es unknown
- 2014-09-09 HK HK14109110.0A patent/HK1195731A1/zh unknown
-
2015
- 2015-07-27 US US14/809,856 patent/US9249397B2/en active Active
- 2015-11-18 JP JP2015225934A patent/JP6000432B2/ja active Active
-
2016
- 2016-03-08 AU AU2016201487A patent/AU2016201487B2/en active Active
- 2016-05-30 CY CY20161100468T patent/CY1117861T1/el unknown
- 2016-06-22 SM SM201600194T patent/SMT201600194B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140734A1 (es) | Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismas | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| ECSP23041058A (es) | Formulación subcutánea de anticuerpo anti-her2 | |
| ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
| PH12014502778B1 (en) | Antibody formulation | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| JOP20150245B1 (ar) | صياغات ذات مفعول طويل من الأنسولين | |
| CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
| BR112016006455A2 (pt) | ?formulação de conjugado de hormônio de crescimento humano de ação prolongada? | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| NZ628398A (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| NZ733366A (en) | Purification of iduronate-2-sulfatase | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| AR091155A1 (es) | Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion | |
| UY33525A (es) | Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición | |
| BR112014002173A2 (pt) | proteínas purificadas | |
| MX2022002728A (es) | Composiciones y metodos para el tratamiento de infecciones virales. | |
| ECSP20032084A (es) | Formulaciones de composiciones de vacuna contra el virus del dengue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |